Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 7:38 PM
Ignite Modification Date:
2025-12-25 @ 5:18 PM
NCT ID:
NCT02267603
Group ID:
EG000
Title:
Treatment (Pembrolizumab)
Description:
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression\* or unacceptable toxicity.
\* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years.
Laboratory Biomarker Analysis: Ancillary studies
Pembrolizumab: Given IV
Deaths Number Affected:
16
Deaths Number At Risk:
None
Serious Number Affected:
22
Serious Number At Risk:
50
Other Number Affected:
50
Other Number At Risk:
50
Study:
NCT02267603
Results Section:
NCT02267603
Adverse Events Module:
NCT02267603